Ionis Pharmaceuticals, Inc. (IONS) Stock: Surges as Phase 3 ALS Trial Delivers Positive Results

TLDR Ionis shares rise 2.58% after positive Phase 3 ulefnersen trial results emerge. Ulefnersen meets the FUSION primary endpoint with strong statistical significance. The FUS-ALS study also records improvements across several key secondary endpoints. Otsuka plans FDA discussions and explores expedited regulatory approval pathways. Ionis remains eligible for milestone payments and royalties under the Otsuka [...]

The post Ionis Pharmaceuticals, Inc. (IONS) Stock: Surges as Phase 3 ALS Trial Delivers Positive Results appeared first on Blockonomi.